Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Policy & Advocacy
    • Health Equity
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in Trial
    • Volunteer
    • Events
    • Resources
  • Store
    • Learning
    • Apparel
    • Accessories
    • Bookshop
    • 7 Principles
Login
  • Donate
0

Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Study Timeline

Q4 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On March 14, 2023, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Read the Q4 2022 progress report here.
March 14, 2023

FDA Provides Additional Guidance for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On January 19, 2023, the FDA advised MAPS that cannabis used in clinical trials is defined as a drug product, rather than a botanical raw material, for the purposes of microbiological testing acceptance …
January 19, 2023

FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On December 16, 2022, the FDA advised MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued due to “insufficient information …
December 16, 2022

MAPS Submits Revised Protocol for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On November 16, 2022, MAPS submitted a revised protocol to the FDA in response to hold issues identified in the Agency’s Continued Partial Clinical Hold letters dated May 10 and December 27, 2021. …
November 16, 2022

October 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On October 15, 2022, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Previous progress reports were released for quarters ending in January, April, and July. …
October 15, 2022

Response from FDA Regarding Request to Lift Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On August 30, 2022, the FDA responded to MAPS’ request to lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2), citing an incomplete response to the hold. …
August 30, 2022

Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Continued Partial Clinical Hold Response

On August 16, 2022, MAPS submitted a complete response to the FDA addressing the continued partial clinical hold letter, received on December 27, 2021.
August 16, 2022

Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)

On July 21, 2022, a general medical and psychiatric practice in Steinheim, Germany, released a statement about their use of cannabis to treat patients with symptoms of posttraumatic stress disorder (PTSD). …
July 31, 2022

July 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On July 15, 2022, MAPS released a grant progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Previous grant reports were released in January and April. Read the July 2022 grant …
July 15, 2022

Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Regulatory Correspondences with FDA

Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
June 13, 2022

April 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On April 15, 2022, MAPS wrote the second progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The first report was for the reporting period ending January 15, 2022. Read the …
April 15, 2022

January 2022 Quarterly Performance Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

On January 14, 2022, MAPS released the first MRA VMR Grant Update for the reporting period ending January 15, 2022 for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The quarterly performance …
January 15, 2022

Posts navigation

Page 1 Page 2 Older Posts
Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Health Equity
    • Policy & Advocacy
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up



  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2022 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Proudly powered by WordPress. Hosted by Pressable.